Dan O’Day’s to-do list for Gilead: Recruit a Kite CEO, press the pedal on next-gen cell therapies and start buying stuff
Dan O’Day has had a chance to kick the tires at Gilead and take it out for a spin. And he took considerable time in his first appearance as CEO during the much-anticipated Q1 call on Thursday night to explain his strategy for the bellwether biotech.
Just don’t look for a lot of exciting detail from his first performance, which drew a few muffled yawns and mixed reviews from analysts who have been waiting years for Gilead to do something even half as exciting as hep C again.
Translating the dry parlance of biotech finance, which O’Day mastered at Roche’s Basel headquarters, he’s determined that one of the best ways to stay on top of the cell therapy business is to bring in a new CEO specifically for his CAR-T company Kite, where they expect to bring on next-gen technology like off-the-shelf therapies as competition breathes down their back.
Basic subscription required
Unlock this story instantly and join 57,800+ biopharma pros reading Endpoints daily — and it's free.